The most award winning
healthcare information source.
TRUSTED FOR FOUR DECADES.
Two new "smart bomb" drugs that target specific proteins needed for tumor growth have produced promising results in clinical trials against a number of cancers, scientists said at a recent American Association for Cancer Research conference in Miami, as reported by Reuters.
AstraZeneca’s tablet Iressa and ImClone’s competing injectable product C225 are the first in a new class of drugs that block the epidermal growth factor receptor (EGFR).
Phase II trial results showed Iressa succeeded in shrinking lung tumors by at least half in 18.7% of seriously ill patients who failed to respond to conventional chemotherapy. In 52.9% of patients the disease stabilized; in 34% the cancer had not grown after four months.
The overall response rate was "much higher" than with standard chemotherapy, while the side effects — primarily diarrhea and skin rash — were minimal, said Jose Baselga, MD, of Vall d’Hebron University Hospital in Barcelona, Spain.